

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (Currently Amended) A medicament for promoting memory consolidation, which comprises, as an active ingredient, a non-natural retinoid, ~~preferably a retinoid~~ having a basic skeleton comprising an aromatic ring bound with an aromatic carboxylic acid or tropolone bound by means of a bridging group.

2. (Original) The medicament according to claim 1, which is used as a medicament for prophylactic and/or therapeutic treatment of dysfunction of memory consolidation associated with a neurodegenerative disease.

3. (Currently Amended) The medicament according to claim 1 ~~or 2~~, wherein the retinoid is a retinoid that binds to the retinoic acid receptor (RAR) subtype α and subtype β , and does not substantially bind to the retinoic acid receptor subtype γ .

4. (Original) The medicament according to claim 3, wherein the retinoid has a basic skeleton comprising a substituted phenyl group bound with benzoic acid by means of a bridging group.

5. (Original) The medicament according to claim 4, wherein the retinoid is 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid or 4-[(3,5-bis-trimethylsilylphenyl)carboxamido]benzoic acid.

6 (Original) A medicament for prophylactic and/or therapeutic treatment of a neurodegenerative disease, which comprises, as an active ingredient, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid or 4-[(3,5-bis-trimethylsilylphenyl)carboxamido]benzoic acid.